Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia

Oncoimmunology. 2023 Nov 3;12(1):2276490. doi: 10.1080/2162402X.2023.2276490. eCollection 2023.


Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. It is characterized by a high dependency on interactions with the surrounding immune landscape, highlighting its suitability for immune-mediated therapeutic interventions. We recently revealed that the cytokine IL-27 exerts a strong anti-tumor role in CLL through a T-cell-mediated mechanism.

Keywords: CD8+ T cells; Cytokine; IL-27; immunotherapy; leukemia.

MeSH terms

  • Adult
  • Cytokines
  • Humans
  • Immunosuppression Therapy
  • Interleukin-27*
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • T-Lymphocytes


  • Interleukin-27
  • Cytokines

Grants and funding

This work was supported by grants from the Luxembourg National Research Fund (FNR) and Fondation Cancer, Luxembourg to EM and JP (C20/BM/14582635 and C20/BM/14592342) and from Fonds National de la Recherche Scientifique (FNRS)-Télévie to IFB and GP (7.4501.18, 7.4529.19, 7.6518.20, and 7.6603.21).